-
UBS Steps To Sidelines on Depomed, Citing Limited Upside; Stock Sinks ~6%
Thursday, July 7, 2016 - 10:28am | 300Read More...Depomed Inc (NASDAQ: DEPO) shares have surged about 25 percent since mid-February, and UBS’ Ami Fadia believes there is limited upside going forward. Fadia downgraded the rating on the company from Buy to Neutral, with a price target of $20. Limited Upside The analyst believes there could be...
-
This Analyst Loves Depomed And Its Nucynta Prescription
Friday, August 28, 2015 - 3:28pm | 343Read More...In a report issued Friday, Roth Capital analyst Scott R. Henry provided an update of prescriptions for Nucynta, a franchise recently acquired by Depomed Inc (NASDAQ: DEPO), which he believes is now the primary fundamental focus for the company’s investors. The firm anticipates flattish...
-
JPMorgan Cut Its Johnson & Johnson Forecast Before Earnings, But Why?
Monday, April 6, 2015 - 3:00pm | 304Read More...In a report published Monday, JPMorgan analyst Michael Weinstein discussed Johnson & Johnson (NYSE: JNJ)'s upcoming first quarter report, scheduled for Tuesday, April 14. Weinstein noted that he is expecting a largely in-line quarter on the top line given an improved pharmaceutical...
